Journal of Clinical and Investigative Dermatology
Research Article
Two different Bioclinical profiles of Chronic Urticaria suggested by basophil number and Reactivity
Dzvig AC2, Lefevre MA1, Durieux C1, Manuel N3, Biron CA 3, Chazelle M3, Garcin A3, Perrot JL3 and Lambert C1,2*
1Immunology laboratory, University Hospital, France
2Allergology unit, University Hospital, France
3Department of Dermatology, University Hospital, France
4Department of Clinical research innovation and pharmacology (URCIP),University Hospital, France
*Address for Correspondence: Lambert C, Laboratoire d’Immunologie, pole de Biologie, Hop Nord CHU SaintEtienne,42055 Saint-Etienne Cedex 2, France; Tel: 33 477120513; Fax: 33
477120552; Email: claude.lambert@chu-st-etienne.fr
Submission: 22 May, 2021
Accepted: 24 June, 2021
Published: 30 June, 2021
Copyright: ©2021 Dzvig AC, et al. This is an open access article distributed
under the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work
is properly cited.
Abstract
Chronic Urticaria (CU): is an heterogeneous disease supposed to be
due to spontaneous release of histamine from unclarified activation of mast
cell or basophil through IgE receptor pathway but treatment targeting either
histamine or IgE are not always successful. The aim of this study was to
explore Basophil phenotyping and functionality to better classify CU.
Methods: the prospective, clinical study enrolled 31 CU and 29 age and
sex matched controls. Basophils were analyzed by flow cytometry.
Results and Discussion: Our CU population demography was very
similar to cohorts previously reported. CU were active for 5.58+5.4 years and
severe (UAS7 = 25.8+10). Serum IgE were higher than 114kU/L in 36.8%
CU vs 12.0% HC. Serum tryptase was higher than 7µg/L in 20%. Basophil
represented less than 0.1% of leukocytes in 32.3% CU and even more in
case of recent flares. Ex vivo basophil activation was defective in 75.9% of
CU vs 31% of HC. However despite an active disease, 41.9% of patients kept
a high basophil count and 7 (24.1%) a high reactivity with low serum tryptase
and low activation profile suggesting their basophils are not the main effector
in the diseases.
Conclusions: Monitoring Basophil count and ex vivo reactivity together
with the level of IgE should help in suspecting the basophil and IgE involvement
or alternative mechanisms of CU. This could lead to a classification of CU in
its heterogeneity and help predicting its response to anti-histaminic or antiIgE
therapies.